HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kamel, E. M. Articles by Steinert, H. C. Search for Related Content PubMed PubMed Citation Articles by Kamel, E. M. Articles by Steinert, H. C.

Whole-Body ¹⁸F-FDG PET Improves the Management of Patients with Small Cell Lung Cancer

¹ Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zurich, Switzerland
² Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland

The aim of this study was to evaluate the impact of whole-body ¹⁸F-FDG PET on staging and managing patients with small cell lung cancer (SCLC). Methods: The treatment records of 42 consecutive patients (27 men, 15 women; mean age, 62 y; age range, 45–83 y) with SCLC were reviewed. Whole-body ¹⁸F-FDG PET was performed for initial staging in 24 patients and for restaging after chemotherapy or radiation treatment in 20 patients. Two patients of the initial staging group were restaged with PET after therapy. PET findings were correlated with clinical and radiologic findings (CT of the chest and abdomen, bone scan, and CT or MRI of the brain). The impact of PET on staging and management decisions was determined. Results: For 12 of 42 patients (29%), PET results changed the patient’s management. In 8 patients (19%), PET resulted in a change of radiation therapy because of the detection of previously unknown tumor foci. Adjuvant radiation therapy was cancelled in 3 patients. A change of radiation field and volume was necessary in 5 patients. In 1 patient, PET results excluded extensive disease, which permitted surgical resection of the tumor. Chemotherapy was discontinued in 2 patients and restarted in 1 patient on the basis of the PET findings. In 5 patients (12%), PET excluded malignancy as the suspicious lesions found with conventional cross-sectional imaging did not take up ¹⁸F-FDG. Conclusion: The results of this study show that ¹⁸F-FDG PET has a major impact on the management of patients with SCLC, influencing both the stage and the management in 29% of patients. PET is a highly valuable tool for accurate target definition of radiation treatment by reducing the probability of overlooking involved areas.

Key Words: ¹⁸F-FDG PET • small cell lung cancer • management • tumor staging

This article has been cited by other articles:

				D. Uesaka, Y. Demura, T. Ishizaki, S. Ameshima, I. Miyamori, M. Sasaki, Y. Fujibayashi, and H. Okazawa Evaluation of Dual-Time-Point 18F-FDG PET for Staging in Patients with Lung Cancer J. Nucl. Med., October 1, 2008; 49(10): 1606 - 1612. [Abstract] [Full Text] [PDF]

				D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]

				D. J. Samson, J. Seidenfeld, G. R. Simon, A. T. Turrisi III, C. Bonnell, K. M. Ziegler, and N. Aronson Evidence for Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 314S - 323S. [Abstract] [Full Text] [PDF]

				G. R. Simon and A. Turrisi Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 324S - 339S. [Abstract] [Full Text] [PDF]

				S. Chong, K. S. Lee, B.-T. Kim, J. Y. Choi, C. A Yi, M. J. Chung, D.-K. Oh, and J.-Y. Lee Integrated PET/CT of Pulmonary Neuroendocrine Tumors: Diagnostic and Prognostic Implications Am. J. Roentgenol., May 1, 2007; 188(5): 1223 - 1231. [Abstract] [Full Text] [PDF]

				B. Fischer, J Mortensen, S. Langer, A Loft, A. Berthelsen, B. Petersen, G Daugaard, U Lassen, and H. Hansen A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis Ann. Onc., February 1, 2007; 18(2): 338 - 345. [Abstract] [Full Text] [PDF]

				M. B. Lobrano Partnerships in Oncology and Radiology: The Role of Radiology in the Detection, Staging, and Follow-up of Lung Cancer Oncologist, July 1, 2006; 11(7): 774 - 779. [Abstract] [Full Text] [PDF]

				T. Bunyaviroch and R. E. Coleman PET Evaluation of Lung Cancer J. Nucl. Med., March 1, 2006; 47(3): 451 - 469. [Full Text] [PDF]

				E. M. Kamel, M. Thumshirn, K. Truninger, M. Schiesser, M. Fried, B. Padberg, D. Schneiter, S. J. Stoeckli, G. K. von Schulthess, and K. D.M. Stumpe Significance of Incidental 18F-FDG Accumulations in the Gastrointestinal Tract in PET/CT: Correlation with Endoscopic and Histopathologic Results J. Nucl. Med., November 1, 2004; 45(11): 1804 - 1810. [Abstract] [Full Text] [PDF]

				J. D. Bradley, F. Dehdashti, M. A. Mintun, R. Govindan, K. Trinkaus, and B. A. Siegel Positron Emission Tomography in Limited-Stage Small-Cell Lung Cancer: A Prospective Study J. Clin. Oncol., August 15, 2004; 22(16): 3248 - 3254. [Abstract] [Full Text] [PDF]

				G. W. Goerres, G. K. von Schulthess, and H. C. Steinert Why Most PET of Lung and Head-and-Neck Cancer Will Be PET/CT J. Nucl. Med., January 1, 2004; 45(90010): 66S - 71. [Abstract] [Full Text] [PDF]